Tianda Pharmaceuticals Limited (HKG:0455)
Hong Kong · Delayed Price · Currency is HKD 0.1080
0.00 (0.00%)
At close: Feb 13, 2026
Tianda Pharmaceuticals Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 310.5 | 329.94 | 532.09 | 546.69 | 509.96 | 474.33 | |
Revenue Growth (YoY) | -19.28% | -37.99% | -2.67% | 7.20% | 7.51% | -3.49% |
Cost of Revenue | 177.74 | 177.91 | 276.56 | 295.17 | 268.73 | 215.34 |
Gross Profit | 132.76 | 152.02 | 255.53 | 251.52 | 241.22 | 258.99 |
Selling, General & Admin | 181.87 | 192.89 | 271.45 | 285.52 | 269.46 | 281.52 |
Research & Development | 12.15 | 13.28 | 13.11 | 36.15 | 15.86 | 11.83 |
Operating Expenses | 194.02 | 206.17 | 284.56 | 321.67 | 285.32 | 293.35 |
Operating Income | -61.26 | -54.15 | -29.02 | -70.14 | -44.1 | -34.36 |
Interest Expense | -4.25 | -4.85 | -4.95 | -6.72 | -0.73 | -0.57 |
Interest & Investment Income | 0.57 | 1.1 | 3.03 | 4.34 | 2.3 | 3.23 |
Currency Exchange Gain (Loss) | 0.05 | -0.11 | 0.48 | -0.21 | 1.07 | -0.5 |
Other Non Operating Income (Expenses) | 3.63 | 4.48 | 4.91 | 6.93 | 2.32 | 3.51 |
EBT Excluding Unusual Items | -61.25 | -53.54 | -25.55 | -65.8 | -39.13 | -28.68 |
Impairment of Goodwill | -1.34 | -1.34 | - | - | -1.58 | - |
Gain (Loss) on Sale of Investments | -0.02 | 0.64 | -0.29 | 0.7 | 0.67 | 1.26 |
Gain (Loss) on Sale of Assets | -0.2 | -0.1 | 0.14 | 1.25 | 12.03 | -0.07 |
Other Unusual Items | -0.26 | - | - | - | - | 0.05 |
Pretax Income | -63.07 | -54.34 | -25.69 | -63.85 | -28.02 | -27.44 |
Income Tax Expense | 4.62 | 7.07 | -0.69 | -4.86 | -6.34 | -1.52 |
Earnings From Continuing Operations | -67.69 | -61.41 | -25.01 | -58.99 | -21.68 | -25.92 |
Minority Interest in Earnings | 0.32 | 0.04 | 0.85 | 4.35 | 1.9 | -1.22 |
Net Income | -67.37 | -61.37 | -24.16 | -54.64 | -19.77 | -27.14 |
Net Income to Common | -67.37 | -61.37 | -24.16 | -54.64 | -19.77 | -27.14 |
Shares Outstanding (Basic) | 2,150 | 2,150 | 2,150 | 2,150 | 2,150 | 2,150 |
Shares Outstanding (Diluted) | 2,150 | 2,150 | 2,150 | 2,150 | 2,150 | 2,150 |
EPS (Basic) | -0.03 | -0.03 | -0.01 | -0.03 | -0.01 | -0.01 |
EPS (Diluted) | -0.03 | -0.03 | -0.01 | -0.03 | -0.01 | -0.01 |
Free Cash Flow | 23.12 | -30.3 | -99.04 | 68.63 | -61.98 | -183.32 |
Free Cash Flow Per Share | 0.01 | -0.01 | -0.05 | 0.03 | -0.03 | -0.09 |
Dividend Per Share | - | - | 0.003 | 0.003 | 0.003 | 0.003 |
Dividend Growth | - | - | -25.01% | 33.35% | - | 100.00% |
Gross Margin | 42.76% | 46.08% | 48.02% | 46.01% | 47.30% | 54.60% |
Operating Margin | -19.73% | -16.41% | -5.46% | -12.83% | -8.65% | -7.24% |
Profit Margin | -21.70% | -18.60% | -4.54% | -9.99% | -3.88% | -5.72% |
Free Cash Flow Margin | 7.45% | -9.18% | -18.61% | 12.55% | -12.16% | -38.65% |
EBITDA | -30.87 | -24.47 | -0.95 | -27.88 | -29.64 | -20.84 |
EBITDA Margin | -9.94% | -7.42% | -0.18% | -5.10% | -5.81% | -4.39% |
D&A For EBITDA | 30.39 | 29.68 | 28.07 | 42.26 | 14.46 | 13.53 |
EBIT | -61.26 | -54.15 | -29.02 | -70.14 | -44.1 | -34.36 |
EBIT Margin | -19.73% | -16.41% | -5.45% | -12.83% | -8.65% | -7.24% |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.